摘要
目的探讨双特异性抗体卡度尼利在中晚期肝细胞癌后线治疗中的疗效和安全性。方法回顾性收集并分析中国医学科学院北京协和医学院肿瘤医院深圳医院2022年7月至2023年10月11例中晚期HCC患者的临床资料,均为男性,年龄(55±4)岁。11例患者均使用卡度尼利单药系统治疗方案。记录患者的性别、年龄、肿瘤分期、不良反应等临床资料。结果11例患者的美国东部肿瘤协作组体能状态评分:0分者2例,1分5例,2分者4例;Child-Pugh分级A级9例,B级2例,均为中国肝癌临床分期Ⅲb期。11例患者接受8(6,16)个周期卡度尼利治疗。11例患者随访(12.0±0.7)个月,4例患者获得部分缓解,3例患者稳定,4例患者进展,无完全缓解病例,客观缓解率和疾病控制率分别为36.4%(4/11)和63.6%(7/11)。截至末次随访,11例患者中,1例仍在接受治疗,6例因肿瘤进展更换了治疗方案,4例因疾病进展死亡。11例患者的1年累积生存率为63.6%,中位无进展生存期为9.0个月。11例患者中共5例发生治疗相关1~2级不良反应,均得到有效处理。未观察到与治疗相关的死亡。结论双特异性抗体卡度尼利对于既往接受过治疗后进展的HCC患者有较好的临床疗效和安全性。
Objective To investigate the efficacy and safety of the bispecific antibody cadonilimab in the later-line treatment for intermediate and advanced hepatocellular carcinoma(HCC).Methods Clinical data of 11 male patients,aged(55±4)years,with intermediate or advanced HCC treated with cardonilide at the Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College from July 2022 to October 2023 were retrospectively analyzed.Data such as gender,age,tumor stage,and adverse reactions of patients were recorded.Results The Eastern Cooperative Oncology Group performance status score of the patients are as follows:two patients scored 0,five patients scored 1,and four patients scored 2.There were nine cases with Child-Pugh staging A and two cases with staging B,both of which were China clinical liver cancer staging IIIb.All patients received 8(6,16)cycles of treatment.Patients were followed up for(12.0±0.7)months,with four patients achieving partial remission,three with stable disease,and four with progression of disease,and none with complete remission.The objective remission rate and disease control rate were 36.4%(4/11)and 63.6%(7/11),respectively.As of the last follow-up,among the 11 patients,one continued with same treatment,six had changed treatment protocol due to tumor progression,and four had died due to disease progression.The 1-year cumulative survival rate of patients was 63.6%,with a median progression free survival of 9.0 months.Out of the 11 patients,five experienced treatment-related grade 1-2 adverse reactions,all of which were effectively managed.No treatment-related deaths were observed.Conclusion Cadonilimab demonstrates promising clinical efficacy in advanced HCC patients with disease progression after prior therapies.
作者
田宇
王睿智
姚雪松
宋鹏
车旭
Tian Yu;Wang Ruizhi;Yao Xuesong;Song Peng;Che Xu(Department of Interventional Therapy,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen 518116,China;Department of Dermatology,the 3rd Affiliated Hospital of Shenzhen University,Shenzhen 518001,China;Department of Hepatobiliary Surgery,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Shenzhen 518116,China)
出处
《中华肝胆外科杂志》
2026年第2期99-102,共4页
Chinese Journal of Hepatobiliary Surgery
关键词
癌
肝细胞
免疫检查点抑制剂
治疗进展
免疫联合治疗
Carcinoma,hepatocellular
Immune checkpoint inhibitors
Treatment progress
Immunotherapy combination
